Načítá se...
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib is a targeted drug to treat myelofibrosis (MF). Ruxolitinib has significant advantages in spleen reduction and increasing 5-year overall survival (OS), and ruxolitinib-based combinations might provide more benefits than ruxolitinib monotherapy. In this review, we focus on the data of rux...
Uloženo v:
| Vydáno v: | Ann Hematol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7237512/ https://ncbi.nlm.nih.gov/pubmed/32333155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04028-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|